Feds Fumble 7-OH Ban Again: Why 7-Star, Opia, and Press’d Are Still Fully Legal

Despite the DEA’s relentless attempts to crack down on the kratom community, highly concentrated 7-hydroxymitragynine (7-OH) brands like 7-Star, Opia, 7OHMZ, Press’d, and Hydroxie still remains completely federally legal after November 13, 2026. The agency has repeatedly stumbled in its efforts to outlaw these life-changing products, continuing a decade-long pattern of bureaucratic overreach, regulatory delays, and outright failures.

The federal government has essentially failed to execute this ban twice before arriving at the current legal limbo: For many Americans, it is a good thing and perhaps a sign of changing attitudes on the country’s disasterous drug policies.

  • The 2016 Retreat: The DEA first attempted to place kratom’s main compounds into Schedule I in 2016, but was forced into a humiliating withdrawal just weeks later after facing a massive, coordinated backlash from the public and Congress.

  • The July 2026 Surrender: The DEA tried again on July 6, 2026, publishing a notice to ban 7-OH products above a 0.05% threshold. However, following a fierce lawsuit by the American Kratom Association, the agency completely caved and withdrew that notice in October.

Now, the DEA has fumbled the ball again. They published a revised notice in October targeting high-potency extracts, explicitly stating that a temporary scheduling order would take effect “on or after November 13, 2026.” That date came and went, and the Federal Register printed nothing. Because the ban strictly requires official publication to take effect, commercial products like Opia and 7-Star can still be purchased freely and legally without federal criminal penalty today.

For the advocates and everyday users who rely on these extracts for pain management, anxiety relief, and breaking free from traditional opioids, the DEA’s incompetence is a daily blessing.

“Traditional painkillers had me trapped, but finding 7OHMZ gave me my life back,” says one Houston-area advocate. “It’s clean, it’s manageable, and I’m actually functional at work again. Taking this away would be a death sentence for thousands of people who just want a safer alternative.”

Another regular user echoes the sentiment, praising the effectiveness of the concentrated extracts over standard leaf kratom: “When my chronic pain flares up, I don’t want a prescription script, and throwing back handfuls of raw powder wrecks my stomach. I grab a three-pack of Opia or 7-Star from my shop on Washington Ave, and it works instantly without the heavy fog. The fact that the DEA is trying to lump this in with street drugs shows they have no idea how much this helps regular people.”

When and if the DEA finally manages to get its paperwork together, the incoming order threatens to instantly outlaw the business model for these specific, highly effective brands. The proposed rule establishes an arbitrary threshold: 7-OH and its synthetic cousin mitragynine pseudoindoxyl (MP) would become Schedule I substances if they exceed 1 milligram per gram in solid products, 1 milligram per milliliter in liquids, or if the natural kratom alkaloid mitragynine is present at a ratio of less than 100-to-1.

Because brands like 7-Star, Press’d, and Opia are expertly formulated to deliver targeted relief by maximizing 7-OH well beyond those restrictive natural leaf ratios, they are squarely in the DEA’s crosshairs. But until the federal government actually pulls the trigger, the 7-OH community is winning the waiting game.

Leave a Reply

Your email address will not be published. Required fields are marked *

FCRA Disclaimer: This website is NOT a Consumer Reporting Agency and data cannot be used for employment, credit, or tenant screening.FCRA Disclaimer: This website is NOT a Consumer Reporting Agency and data cannot be used for employment, credit, or tenant screening.